AOD-9604 is a high-purity peptide offered in a 5mg lyophilized powder format, intended strictly for laboratory research and development purposes. Manufactured to exceed 99% purity and tested using both HPLC and LC-MS protocols, this peptide is supplied in a sterile, sealed vial to ensure stability and integrity.
Recent research & studies
- Synergistic Anti-Obesity Effect of Akkermansia muciniphila AKM Lab-01 and Garcinia cambogia Extract via Gut Microbiota Remodeling in Diet-Induced Obese Mice.
Obesity is a global health crisis driven by complex metabolic dysregulation. Although Akkermansia muciniphila (AKK) has emerged as a promising next-generation probiotic for metabolic health, its synergistic potential with natural anti-obesity compounds remains largely unexplored. Here, we evaluated the combined…
- Dose-Dependent Anti-Obesity and Protective Effects of Chia (Salvia hispanica L.) Seed Oil Against Hematological and Hepatorenal Dysfunction in High-Fat Diet-Fed Mice.
Chia seeds (Salvia hispanica L.) are recognized as a functional food with a nutrient-dense profile and health-promoting properties. In the present study, hexane-extracted chia seed oil was investigated for anti-obesity, hematoprotective, and hepatorenoprotective potentials in high-fat diet (HFD)-induced obese mice.…
- Therapeutic Potential of Water-Based Anatolian Propolis Extract Against CAF Diet-Induced Obesity and Its Metabolic Complications.
This study investigates the anti-obesity effects of water-based Anatolian propolis extract in mice with a cafeteria diet-induced obesity model. The phenolic composition, antioxidant capacity, and α-amylase/α-glucosidase inhibitory effects of the WBAP extract were characterized in vitro. For the in vivo study, 42…
- Intracerebroventricular and intranasal application of alarin reduces body weight in male rats.
Objective: Obesity represents a major public health burden, necessitating novel therapeutic targets. Alarin, one of the most recently discovered members of the galanin neuropeptide family, may be a potential candidate for anti-obesity therapy. Alarin has been shown to reduce food…
- GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.
Glucagon-like peptide-1 receptor agonists have transformed obesity pharmacotherapy by producing substantial weight loss and, for semaglutide in patients with established cardiovascular disease, reducing major cardiovascular events. Integrating these therapies into primary care is constrained by gaps in provider training, clinical…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
